The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …

Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …

Background: Patients with diabetes appear to be at elevated risk of atherothrombotic events.
Objectives: The purpose of this study was to determine the effect of antiplatelet therapy with …

Background—Patients with diabetes mellitus (DM) are at high risk for recurrent
cardiovascular events after acute coronary syndromes, in part because of increased platelet …

Aims Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased
risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the …

Context: diabetes mellitus is a global pandemic. The increased platelet activity may play a
role in the development of vascular complications of this metabolic disorder. The mean …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Cardiovascular disease, particularly coronary artery dis-ease resulting from accelerated
atherosclerosis, is the leading cause of morbidity and mortality in patients with diabetes …

Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated
with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has …